Clinical Trial Update: A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the pharmacokinetics, safety, and mechanism of action of alogabat in children and adolescents with Angelman syndrome with deletion geno…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angelman Syndrome

Drugs mentioned

• Alogabat (alogabat)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Angelman Syndrome | Phase 2 | Status: COMPLETED